Clinical Efficacy Evaluation of 1-Year Subcutaneous Immunotherapy for Artemisia sieversiana Pollen Allergic Rhinitis by Serum Metabolomics
Shi, H.-Y. Pan, C. Ma, T.-T. Chen, Y.-L. Yan, W.-J. Liu, J.-G. Cao, M.-D. Huang, H.-D. Wang, D.-Y. Wang, X.-Y.
Shi, H.-Y.
Pan, C.
Ma, T.-T.
Chen, Y.-L.
Yan, W.-J.
Liu, J.-G.
Cao, M.-D.
Huang, H.-D.
Wang, X.-Y.
Citations
Altmetric:
Alternative Title
Abstract
Subcutaneous immunotherapy is the only treatment that improves the natural progression of allergic rhinitis and maintains long-term outcomes after discontinuation of the drug. Metabolomics is increasingly applied in the study of allergic diseases, including allergic rhinitis. However, little is known about the discovery of metabolites that can evaluate clinical efficacy and possible mechanisms of Artemisia sieversiana pollen subcutaneous immunotherapy. Thirty-three patients with Artemisia sieversiana pollen allergic rhinitis significantly improved after 1-year subcutaneous immunotherapy treatment, while ten patients were ineffective. Pre- and post-treatment serum samples from these patients were analyzed by metabolomics based on the combined detection of liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry. As a result, L-Tyrosine can be a potential biomarker because of its opposite trend in effective patients and ineffective patients. And mechanism of immunotherapy may be closely related to NO and nitric oxide synthase. The discovery of potential biomarkers and metabolic pathways has contributed to the in-depth study of mechanisms of subcutaneous immunotherapy treatment of Artemisia sieversiana pollen allergic rhinitis. © Copyright © 2020 Shi, Pan, Ma, Chen, Yan, Liu, Cao, Huang, Wang, Wang and Wei.
Keywords
clinical efficacy, GC-MS, LC-MS, metabolomics, seasonal allergic rhinitis, subcutaneous immunotherapy
Source Title
Frontiers in Pharmacology
Publisher
Frontiers Media S.A.
Series/Report No.
Collections
Rights
Attribution 4.0 International
Date
2020
DOI
10.3389/fphar.2020.00305
Type
Article